Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $87 from $82 and keeps a Buy rating on the shares citing increased odds of success assumptions in second-line non-small cell lung cancer after the company provided a clinical data update on its RAS inhibitor pipeline that the the firm believes was “generally positive and further de-risks RVMD’s clinical development plans in PDAC, NSCLC, and CRC.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines price target raised to $71 from $63 at JPMorgan
- Revolution Medicines announces $600M common stock offering
- Revolution Medicines price target raised to $80 from $70 at Stifel
- Revolution Medicines provides updates from RAS(ON) inhibitor combo studies
- Revolution Medicines provides updates from RAS(ON) inhibitor portfolio
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
